{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:58:14Z","timestamp":1791903494256,"version":"4.3.4"},"reference-count":221,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012728","name":"Frederick National Laboratory for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN261201500003I"],"award-info":[{"award-number":["HHSN261201500003I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.drup.2021.100796","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T21:48:27Z","timestamp":1639604907000},"page":"100796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":382,"special_numbering":"C","title":["Anticancer drug resistance: An update and perspective"],"prefix":"10.1016","volume":"59","author":[{"given":"Ruth","family":"Nussinov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Jung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunbum","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2021.100796_bib0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nchembio760","article-title":"Allosteric inhibitors of Bcr-abl-dependent cell proliferation","volume":"2","author":"Adrian","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drup.2021.100796_bib0010","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/s41467-021-21884-z","article-title":"Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer","volume":"12","author":"Aissa","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2021.100796_bib0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41588-019-0564-y","article-title":"Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer","volume":"52","author":"Akdemir","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drup.2021.100796_bib0020","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41588-020-0708-0","article-title":"Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure","volume":"52","author":"Akdemir","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drup.2021.100796_bib0025","series-title":"Molecular Biology","article-title":"Cancer as a microevolutionary process","author":"Alberts","year":"2002"},{"key":"10.1016\/j.drup.2021.100796_bib0030","doi-asserted-by":"crossref","first-page":"188310","DOI":"10.1016\/j.bbcan.2019.188310","article-title":"Mechanisms of acquired tumor drug resistance","volume":"1872","author":"Aleksakhina","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0035","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/ejhg.2017.65","article-title":"Genotype and phenotype spectrum of NRAS germline variants","volume":"25","author":"Altmuller","year":"2017","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.drup.2021.100796_bib0040","doi-asserted-by":"crossref","first-page":"100658","DOI":"10.1016\/j.drup.2019.100658","article-title":"Advanced technological tools to study multidrug resistance in cancer","volume":"48","author":"Andrei","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0045","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ccell.2020.08.003","article-title":"FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer","volume":"38","author":"Arruabarrena-Aristorena","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2021.100796_bib0050","doi-asserted-by":"crossref","first-page":"18326","DOI":"10.1016\/S0021-9258(18)51467-8","article-title":"Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate","volume":"264","author":"Assaraf","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2021.100796_bib0055","doi-asserted-by":"crossref","first-page":"100645","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0060","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"371\u2013385","key":"10.1016\/j.drup.2021.100796_bib0065","first-page":"e318","article-title":"Comprehensive characterization of cancer driver genes and mutations","volume":"173","author":"Bailey","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drup.2021.100796_bib0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drup.2017.05.002","article-title":"Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance","volume":"31","author":"Bar-Zeev","year":"2017","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0075","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome - biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cpt.1938","article-title":"Rare mutations in cancer drug resistance and implications for therapy","volume":"108","author":"Beckman","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drup.2021.100796_bib0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev-pharmtox-010716-105106","article-title":"Targeting epigenetics in cancer","volume":"58","author":"Bennett","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.drup.2021.100796_bib0090","doi-asserted-by":"crossref","first-page":"13964","DOI":"10.1074\/jbc.RA119.009131","article-title":"Structural basis of the atypical activation mechanism of KRAS(V14I)","volume":"294","author":"Bera","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2021.100796_bib0095","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nm.3841","article-title":"Studying clonal dynamics in response to cancer therapy using high-complexity barcoding","volume":"21","author":"Bhang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.trecan.2021.01.009","article-title":"Group behavior and emergence of cancer drug resistance","volume":"7","author":"Bhattacharya","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0105","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1093\/annonc\/mdu464","article-title":"Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset","volume":"25","author":"Blons","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2021.100796_bib0110","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1038\/ctg.2016.18","article-title":"KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma","volume":"7","author":"Bournet","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.drup.2021.100796_bib0115","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00280-013-2300-0","article-title":"Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and\/or tumor cell apoptosis","volume":"72","author":"Bousquet","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.drup.2021.100796_bib0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcp.2007.03.028","article-title":"C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells","volume":"74","author":"Bram","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drup.2021.100796_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006981","article-title":"Finding driver mutations in cancer: elucidating the role of background mutational processes","volume":"15","author":"Brown","year":"2019","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.drup.2021.100796_bib0130","doi-asserted-by":"crossref","first-page":"100761","DOI":"10.1016\/j.drup.2021.100761","article-title":"Cross-resistance and drug sequence in prostate cancer","volume":"56","author":"Buck","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0135","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.drup.2007.06.001","article-title":"Roots of imatinib resistance: a question of self-renewal?","volume":"10","author":"Burchert","year":"2007","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0140","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/2159-8290.CD-14-0729","article-title":"Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma","volume":"4","author":"Burd","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2021.100796_bib0145","first-page":"132","article-title":"The cell biology behind the oncogenic PIP3 lipids","author":"Carrera","year":"2019","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.drup.2021.100796_bib0150","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/0008-5472.CAN-04-0085","article-title":"A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors","volume":"64","author":"Chen","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2021.100796_bib0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13059-020-01954-z","article-title":"Comprehensive assessment of computational algorithms in predicting cancer driver mutations","volume":"21","author":"Chen","year":"2020","journal-title":"Genome Biol."},{"key":"10.1016\/j.drup.2021.100796_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.118.016253","article-title":"Personal mutanomes meet modern oncology drug discovery and precision health","volume":"71","author":"Cheng","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drup.2021.100796_bib0165","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41588-020-00774-y","article-title":"Comprehensive characterization of protein-protein interactions perturbed by disease mutations","volume":"53","author":"Cheng","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drup.2021.100796_bib0170","doi-asserted-by":"crossref","first-page":"100744","DOI":"10.1016\/j.drup.2021.100744","article-title":"Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer","volume":"55","author":"Chiappa","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0175","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0180","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12885-016-2999-1","article-title":"Molecular chess? Hallmarks of anti-cancer drug resistance","volume":"17","author":"Cree","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0190","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ghir.2014.10.002","article-title":"The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?","volume":"25","author":"Crudden","year":"2015","journal-title":"Growth Horm. IGF Res."},{"key":"10.1016\/j.drup.2021.100796_bib0195","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1038\/s41598-019-44226-y","article-title":"Metastatic tumor burden and loci as predictors of first line sunitinib treatment efficacy in patients with renal cell carcinoma","volume":"9","author":"Czarnecka","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2021.100796_bib0200","series-title":"New research uncovers how cancers with common mutation develop resistance to targeted drugs","author":"Dana-Farber Cancer Institute","year":"2021"},{"key":"10.1016\/j.drup.2021.100796_bib0205","doi-asserted-by":"crossref","first-page":"100754","DOI":"10.1016\/j.drup.2021.100754","article-title":"Therapeutic strategies to overcome taxane resistance in cancer","volume":"55","author":"Das","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drup.2021.100796_bib0215","series-title":"Are All RAS Proteins Created Equal in Cancer?","author":"Der","year":"2014"},{"key":"10.1016\/j.drup.2021.100796_bib0220","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2407-5-78","article-title":"Cancer cell adaptation to chemotherapy","volume":"5","author":"Di Nicolantonio","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0225","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20200401","article-title":"Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels","volume":"40","author":"Du","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.drup.2021.100796_bib0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/cancers13010151","article-title":"Mechanisms of resistance to KRAS(G12C) inhibitors","volume":"13","author":"Dunnett-Kane","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2021.100796_bib0235","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.molcel.2014.05.015","article-title":"Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance","volume":"54","author":"Easwaran","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.drup.2021.100796_bib0240","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.drup.2007.09.001","article-title":"Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches","volume":"10","author":"Eberle","year":"2007","journal-title":"Drug Resist. Updat."},{"issue":"431\u2013443","key":"10.1016\/j.drup.2021.100796_bib0245","first-page":"e435","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2021.100796_bib0250","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.drup.2021.100796_bib0255","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.gendis.2018.06.003","article-title":"Epigenetic mechanisms as a new approach in cancer treatment: an updated review","volume":"5","author":"Fardi","year":"2018","journal-title":"Genes Dis."},{"key":"10.1016\/j.drup.2021.100796_bib0260","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrg.2016.13","article-title":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression","volume":"17","author":"Feinberg","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.drup.2021.100796_bib0265","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.drup.2021.100796_bib0270","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.18632\/oncotarget.7459","article-title":"Drug resistance in cancer: molecular evolution and compensatory proliferation","volume":"7","author":"Friedman","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100796_bib0275","doi-asserted-by":"crossref","first-page":"100770","DOI":"10.1016\/j.drup.2021.100770","article-title":"Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function","volume":"57","author":"Gao","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0280","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","article-title":"Circumventing cancer drug resistance in the era of personalized medicine","volume":"2","author":"Garraway","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2021.100796_bib0285","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033415","article-title":"The evolution and ecology of resistance in cancer therapy","volume":"8","author":"Gatenby","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0290","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2017.10.003","article-title":"Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins","volume":"32","author":"Genovese","year":"2017","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0295","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","article-title":"The evolutionary history of 2,658 cancers","volume":"578","author":"Gerstung","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drup.2021.100796_bib0300","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1021\/mp200310u","article-title":"Changing the energy habitat of the cancer cell in order to impact therapeutic resistance","volume":"8","author":"Getzenberg","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2021.100796_bib0305","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0310","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1073\/pnas.81.18.5704","article-title":"Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules","volume":"81","author":"Gibbs","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2021.100796_bib0315","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.drup.2016.06.008","article-title":"The pharmacogenomics of drug resistance to protein kinase inhibitors","volume":"28","author":"Gillis","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0320","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/1471-2407-9-300","article-title":"Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)","volume":"9","author":"Glaysher","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0325","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/sj.bjc.6605817","article-title":"Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy (for the NHS Collaborative Research Programme for Predictive Oncology)","volume":"103","author":"Glaysher","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0330","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.bcp.2012.01.033","article-title":"Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells","volume":"83","author":"Goler-Baron","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drup.2021.100796_bib0335","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0340","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.drup.2021.100796_bib0345","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0350","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0355","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1038\/s41467-020-18504-7","article-title":"mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability","volume":"11","author":"Gremke","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2021.100796_bib0360","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","article-title":"Drug resistance in cancer: mechanisms and tackling strategies","volume":"72","author":"Haider","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.drup.2021.100796_bib0365","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.trecan.2017.08.006","article-title":"KRAS alleles: the devil is in the detail","volume":"3","author":"Haigis","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0370","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/2159-8290.CD-12-0237","article-title":"Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth","volume":"2","author":"Harbinski","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2021.100796_bib0375","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008970","article-title":"Mathematical modeling of multiple pathways in colorectal carcinogenesis using dynamical systems with Kronecker structure","volume":"17","author":"Haupt","year":"2021","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.drup.2021.100796_bib0385","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.drup.2021.100796_bib0390","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2021.100796_bib0395","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab--mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0400","doi-asserted-by":"crossref","first-page":"100769","DOI":"10.1016\/j.drup.2021.100769","article-title":"The role of endolysosomal trafficking in anticancer drug resistance","volume":"57","author":"Hussein","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0405","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.1158\/0008-5472.CAN-05-2021","article-title":"Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance","volume":"65","author":"Ifergan","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2021.100796_bib0410","doi-asserted-by":"crossref","first-page":"102438","DOI":"10.1016\/j.isci.2021.102438","article-title":"The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane","volume":"24","author":"Jang","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.drup.2021.100796_bib0415","doi-asserted-by":"crossref","first-page":"100683","DOI":"10.1016\/j.drup.2020.100683","article-title":"Long non-coding RNAs as a determinant of cancer drug resistance: towards the overcoming of chemoresistance via modulation of lncRNAs","volume":"50","author":"Jiang","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0420","doi-asserted-by":"crossref","first-page":"100752","DOI":"10.1016\/j.drup.2021.100752","article-title":"Emerging role of autophagy in anti-tumor immunity: implications for the modulation of immunotherapy resistance","volume":"56","author":"Jiang","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0425","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2021.100796_bib0430","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.drup.2021.100796_bib0435","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0440","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.drudis.2020.11.030","article-title":"Addressing the tumour microenvironment in early drug discovery: a strategy to overcome drug resistance and identify novel targets for cancer therapy","volume":"26","author":"Kaemmerer","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drup.2021.100796_bib0445","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0450","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.adcom.2020.11.002","article-title":"Chapter five - FPGA based neural network accelerators","volume":"122","author":"Kim","year":"2021","journal-title":"Adv. Comp."},{"key":"10.1016\/j.drup.2021.100796_bib0455","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41419-019-1601-6","article-title":"AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells","volume":"10","author":"Kim","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2021.100796_bib0460","doi-asserted-by":"crossref","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","article-title":"PubChem in 2021: new data content and improved web interfaces","volume":"49","author":"Kim","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2021.100796_bib0465","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrc2787","article-title":"Targeting the cancer kinome through polypharmacology","volume":"10","author":"Knight","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0470","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cmet.2015.10.005","article-title":"Metabolic mechanisms of drug resistance in leukemia","volume":"22","author":"Knoechel","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.drup.2021.100796_bib0475","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan6566","article-title":"A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer","volume":"9","author":"Kohsaka","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0480","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1038\/onc.2015.513","article-title":"Epigenomic regulation of oncogenesis by chromatin remodeling","volume":"35","author":"Kumar","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2021.100796_bib0485","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s13046-019-1240-x","article-title":"Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC","volume":"38","author":"La Monica","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2021.100796_bib0490","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cub.2012.11.031","article-title":"Rare codons regulate KRas oncogenesis","volume":"23","author":"Lampson","year":"2013","journal-title":"Curr. Biol."},{"key":"10.1016\/j.drup.2021.100796_bib0495","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-15-1113","article-title":"Inhibition of casein kinase 1 alpha prevents acquired drug resistance to erlotinib in EGFR-Mutant non-small cell lung cancer","volume":"75","author":"Lantermann","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2021.100796_bib0500","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.drup.2021.100796_bib0505","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/bjc.2012.10","article-title":"Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents","volume":"106","author":"Le Tourneau","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0510","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drup.2012.01.004","article-title":"Starvation, detoxification, and multidrug resistance in cancer therapy","volume":"15","author":"Lee","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0515","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/ijms21031102","article-title":"Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity","volume":"21","author":"Lee","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2021.100796_bib0520","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12935-021-01746-w","article-title":"Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance","volume":"21","author":"Levin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drup.2021.100796_bib0525","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100720","article-title":"Surmounting cancer drug resistance: new insights from the perspective of N(6)-methyladenosine RNA modification","volume":"53","author":"Li","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0535","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ceb.2017.02.007","article-title":"PI3K signaling in cancer: beyond AKT","volume":"45","author":"Lien","year":"2017","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.drup.2021.100796_bib0540","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","article-title":"Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy","volume":"12","author":"Lim","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2021.100796_bib0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007701","article-title":"Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes","volume":"16","author":"Liu","year":"2020","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.drup.2021.100796_bib0550","doi-asserted-by":"crossref","first-page":"26863","DOI":"10.1073\/pnas.1910301116","article-title":"Extensive subclonal mutational diversity in human colorectal cancer and its significance","volume":"116","author":"Loeb","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2021.100796_bib0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100703","article-title":"Genetic biomarkers of drug resistance: a compass of prognosis and targeted therapy in acute myeloid leukemia","volume":"52","author":"Long","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0560","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1021\/acs.chemrev.5b00542","article-title":"Ras conformational ensembles, allostery, and signaling","volume":"116","author":"Lu","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.drup.2021.100796_bib0565","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1073\/pnas.1821093116","article-title":"Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner","volume":"116","author":"Madsen","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2021.100796_bib0570","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrg3890","article-title":"The effects of chromatin organization on variation in mutation rates in the genome","volume":"16","author":"Makova","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.drup.2021.100796_bib0575","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.drup.2021.100796_bib0580","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1126\/science.aab4082","article-title":"Somatic mutation in cancer and normal cells","volume":"349","author":"Martincorena","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.drup.2021.100796_bib0585","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13073-020-00774-x","article-title":"Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns","volume":"12","author":"Mateo","year":"2020","journal-title":"Genome Med."},{"key":"10.1016\/j.drup.2021.100796_bib0590","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa051918","article-title":"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors","volume":"353","author":"Mellinghoff","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0595","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"611\u2013623","key":"10.1016\/j.drup.2021.100796_bib0600","first-page":"e617","article-title":"Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal","volume":"173","author":"Mitchell","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drup.2021.100796_bib0605","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2021.100796_bib0610","doi-asserted-by":"crossref","first-page":"100","DOI":"10.25259\/IJMIO_26_2020","article-title":"Driver mutations in oncogenesis","volume":"6","author":"Morjaria","year":"2021","journal-title":"Int. J. Mol. Immuno Oncol."},{"key":"10.1016\/j.drup.2021.100796_bib0615","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3389\/fonc.2019.01088","article-title":"A comparative analysis of individual RAS mutations in cancer biology","volume":"9","author":"Munoz-Maldonado","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2021.100796_bib0620","doi-asserted-by":"crossref","first-page":"100663","DOI":"10.1016\/j.drup.2019.100663","article-title":"Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance","volume":"48","author":"Narayanan","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0625","series-title":"Cancer Drug Resistance: Unraveling Its Complexity","author":"National Cancer Institute","year":"2020"},{"key":"10.1016\/j.drup.2021.100796_bib0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007362","article-title":"Cancer epigenetics: moving forward","volume":"14","author":"Nebbioso","year":"2018","journal-title":"PLoS Genet."},{"key":"10.1016\/j.drup.2021.100796_bib0635","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41698-017-0007-0","article-title":"Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma","volume":"1","author":"Neel","year":"2017","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.drup.2021.100796_bib0640","series-title":"Isoform-Specific Ras Expression and Signalling","author":"Newlaczyl","year":"2016"},{"key":"10.1016\/j.drup.2021.100796_bib0645","doi-asserted-by":"crossref","first-page":"100096","DOI":"10.1016\/j.array.2021.100096","article-title":"A comparative study of operational engineering for environmental and compute-intensive applications","volume":"12","author":"Nguyen","year":"2021","journal-title":"Array"},{"key":"10.1016\/j.drup.2021.100796_bib0650","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","article-title":"The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2021.100796_bib0655","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.tips.2014.03.006","article-title":"Unraveling structural mechanisms of allosteric drug action","volume":"35","author":"Nussinov","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drup.2021.100796_bib0660","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.sbi.2015.01.004","article-title":"\u2019Latent drivers\u2019 expand the cancer mutational landscape","volume":"32","author":"Nussinov","year":"2015","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.drup.2021.100796_bib0665","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.18632\/oncotarget.2439","article-title":"The structural basis for cancer treatment decisions","volume":"5","author":"Nussinov","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100796_bib0670","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tips.2017.02.001","article-title":"A new view of pathway-driven drug resistance in tumor proliferation","volume":"38","author":"Nussinov","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drup.2021.100796_bib0675","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1158\/0008-5472.CAN-17-2727","article-title":"Oncogenic ras isoforms signaling specificity at the membrane","volume":"78","author":"Nussinov","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2021.100796_bib0680","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12551-018-0496-2","article-title":"Precision medicine review: rare driver mutations and their biophysical classification","volume":"11","author":"Nussinov","year":"2019","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.drup.2021.100796_bib0685","article-title":"Review: precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers","volume":"15","author":"Nussinov","year":"2019","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.drup.2021.100796_bib0690","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.tips.2019.10.003","article-title":"Why Are Some Driver Mutations Rare?","volume":"40","author":"Nussinov","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drup.2021.100796_bib0695","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.tibs.2020.03.013","article-title":"Are Parallel Proliferation Pathways Redundant?","volume":"45","author":"Nussinov","year":"2020","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.drup.2021.100796_bib0700","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1096\/fj.201901341R","article-title":"Autoinhibition can identify rare driver mutations and advise pharmacology","volume":"34","author":"Nussinov","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.drup.2021.100796_bib0705","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-020-00420-3","article-title":"A new precision medicine initiative at the dawn of exascale computing","volume":"6","author":"Nussinov","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2021.100796_bib0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17460441.2021.1905628","article-title":"Drugging multiple same-allele driver mutations in cancer","volume":"16","author":"Nussinov","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.drup.2021.100796_bib0715","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12551-021-00817-6","article-title":"Ras isoform-specific expression, chromatin accessibility, and signaling","volume":"13","author":"Nussinov","year":"2021","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.drup.2021.100796_bib0720","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2021.100796_bib0725","article-title":"Cancer researchers use evolution to target drug resistance","author":"Offord","year":"2020","journal-title":"The Scientist"},{"key":"10.1016\/j.drup.2021.100796_bib0730","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s00535-012-0664-2","article-title":"Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer","volume":"48","author":"Ogura","year":"2013","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.drup.2021.100796_bib0735","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2021.100796_bib0740","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.drup.2021.100796_bib0745","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.drup.2021.100796_bib0750","doi-asserted-by":"crossref","DOI":"10.3390\/biom9040153","article-title":"The PTEN(-)PI3K axis in cancer","volume":"9","author":"Papa","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.drup.2021.100796_bib0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100779","article-title":"GSK3beta as a novel promising target to overcome chemoresistance in pancreatic cancer","volume":"58","author":"Pecoraro","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0760","series-title":"RAS Genes","author":"Pellicer","year":"2011"},{"key":"10.1016\/j.drup.2021.100796_bib0765","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-pathol-012414-040312","article-title":"Driver and passenger mutations in cancer","volume":"10","author":"Pon","year":"2015","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.drup.2021.100796_bib0770","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-011-1766-x","article-title":"The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin","volume":"133","author":"Pontiggia","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.drup.2021.100796_bib0775","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1158\/2159-8290.CD-18-1220","article-title":"Tissue-specific oncogenic activity of KRAS(A146T)","volume":"9","author":"Poulin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2021.100796_bib0780","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1158\/0008-5472.CAN-19-0122","article-title":"Single-cell analysis reveals a preexisting drug-resistant subpopulation in the luminal breast cancer subtype","volume":"79","author":"Prieto-Vila","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2021.100796_bib0785","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2021.100796_bib0790","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2021.100796_bib0795","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0800","first-page":"609","article-title":"Ras and Ras mutations in cancer","volume":"8","author":"Rajasekharan","year":"2013","journal-title":"Cent. Eur. J. Biol."},{"key":"10.1016\/j.drup.2021.100796_bib0805","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10555-020-09920-8","article-title":"Splice variants of RAS-translational significance","volume":"39","author":"Raso","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.drup.2021.100796_bib0810","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41568-019-0185-x","article-title":"An analysis of genetic heterogeneity in untreated cancers","volume":"19","author":"Reiter","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0815","doi-asserted-by":"crossref","first-page":"100626","DOI":"10.1016\/j.jbc.2021.100626","article-title":"A comprehensive analysis of RAS-effector interactions reveals interaction hotspots and new binding partners","volume":"296","author":"Rezaei Adariani","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2021.100796_bib0820","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0825","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/1389201015666140519123219","article-title":"Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer","volume":"15","author":"Rolfo","year":"2014","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.drup.2021.100796_bib0830","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2147\/OTT.S239336","article-title":"A review of research progress in multidrug-resistance mechanisms in gastric cancer","volume":"13","author":"Ruan","year":"2020","journal-title":"Onco. Ther."},{"key":"10.1016\/j.drup.2021.100796_bib0835","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ccell.2015.02.007","article-title":"In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities","volume":"27","author":"Rubio-Perez","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2021.100796_bib0840","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/cncr.28599","article-title":"Mutational analysis and clinical correlation of metastatic colorectal cancer","volume":"120","author":"Russo","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0845","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molmed.2018.12.009","article-title":"Principles of resistance to targeted Cancer therapy: lessons from basic and translational cancer biology","volume":"25","author":"Sabnis","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0850","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41586-020-2175-2","article-title":"Landscape and function of multiple mutations within individual oncogenes","volume":"582","author":"Saito","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drup.2021.100796_bib0855","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.drup.2019.04.002","article-title":"The TICking clock of EGFR therapy resistance in glioblastoma: target Independence or target compensation","volume":"43","author":"Saleem","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0860","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100646","article-title":"The emergence of drug resistance to targeted cancer therapies: clinical evidence","volume":"47","author":"Sarmento-Ribeiro","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0870","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1158\/1078-0432.CCR-18-0167","article-title":"Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in Philadelphia-Positive leukemias","volume":"24","author":"Schmitt","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2021.100796_bib0875","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2021.100796_bib0880","doi-asserted-by":"crossref","first-page":"100728","DOI":"10.1016\/j.drup.2020.100728","article-title":"The role of alternative splicing in cancer: from oncogenesis to drug resistance","volume":"53","author":"Sciarrillo","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0885","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1038\/s41467-019-11530-0","article-title":"Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients","volume":"10","author":"Serebriiskii","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2021.100796_bib0890","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.drup.2021.100796_bib0895","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41568-019-0228-3","article-title":"KRAS-G12C in the crosshairs","volume":"20","author":"Seton-Rogers","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib0900","doi-asserted-by":"crossref","first-page":"100712","DOI":"10.1016\/j.drup.2020.100712","article-title":"Inhibiting the inhibitors: targeting anti-apoptotic proteins in cancer and therapy resistance","volume":"52","author":"Shahar","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0905","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2021.100796_bib0910","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drup.2021.100796_bib0915","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1073\/pnas.1218173110","article-title":"NMR-based functional profiling of RASopathies and oncogenic RAS mutations","volume":"110","author":"Smith","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drup.2021.100796_bib0920","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1399-0004.2011.01754.x","article-title":"Two novel germline KRAS mutations: expanding the molecular and clinical phenotype","volume":"81","author":"Stark","year":"2012","journal-title":"Clin. Genet."},{"key":"10.1016\/j.drup.2021.100796_bib0925","doi-asserted-by":"crossref","DOI":"10.1177\/1176935117711944","article-title":"Tumor RAS gene expression levels are influenced by the mutational status of RAS genes and both upstream and downstream RAS pathway genes","volume":"16","author":"Stephens","year":"2017","journal-title":"Cancer Inform."},{"key":"10.1016\/j.drup.2021.100796_bib0930","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.drup.2021.100796_bib0935","doi-asserted-by":"crossref","first-page":"100777","DOI":"10.1016\/j.drup.2021.100777","article-title":"Novel nanomedicines to overcome cancer multidrug resistance","volume":"58","author":"Su","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0940","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1002\/cam4.2190","article-title":"Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis","volume":"8","author":"Sun","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.drup.2021.100796_bib0945","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1126\/science.1230184","article-title":"Epigenetic reprogramming in cancer","volume":"339","author":"Suva","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.drup.2021.100796_bib0950","doi-asserted-by":"crossref","first-page":"9966","DOI":"10.1038\/s41598-018-27767-6","article-title":"T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR\/Cas9 system","volume":"8","author":"Tamai","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2021.100796_bib0955","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.gastro.2004.02.021","article-title":"A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient","volume":"127","author":"Tamborini","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2021.100796_bib0960","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2021.100796_bib0965","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2021.100796_bib0970","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.drup.2015.08.004","article-title":"Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach","volume":"23","author":"Taylor","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib0975","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1073\/pnas.1421839112","article-title":"Only three driver gene mutations are required for the development of lung and colorectal cancers","volume":"112","author":"Tomasetti","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drup.2021.100796_bib0980","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1073\/pnas.1412811112","article-title":"K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif","volume":"112","author":"Tsai","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drup.2021.100796_bib0985","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.critrevonc.2016.01.024","article-title":"Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature","volume":"100","author":"van der Wekken","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"391\u2013403","key":"10.1016\/j.drup.2021.100796_bib0990","first-page":"e396","article-title":"Induction of a timed metabolic collapse to overcome cancer chemoresistance","volume":"32","author":"van Gastel","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.drup.2021.100796_bib0995","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.drup.2021.100796_bib1000","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aaw9032","article-title":"Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kalpha inhibitors","volume":"366","author":"Vasan","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.drup.2021.100796_bib1005","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fonc.2015.00282","article-title":"Prediction of cancer drug resistance and implications for personalized medicine","volume":"5","author":"Volm","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2021.100796_bib1010","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.drup.2021.100796_bib1015","doi-asserted-by":"crossref","first-page":"100743","DOI":"10.1016\/j.drup.2021.100743","article-title":"Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance","volume":"54","author":"Wang","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib1020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.drup.2016.07.001","article-title":"Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics","volume":"28","author":"Wijdeven","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib1025","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature11249","article-title":"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors","volume":"487","author":"Wilson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drup.2021.100796_bib1030","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2021.100796_bib1035","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1021\/mp200292c","article-title":"Drug resistance and cellular adaptation to tumor acidic pH microenvironment","volume":"8","author":"Wojtkowiak","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2021.100796_bib1040","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drup.2021.100796_bib1045","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/2159-8290.CD-13-0096","article-title":"Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation","volume":"3","author":"Xu","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2021.100796_bib1050","doi-asserted-by":"crossref","first-page":"100673","DOI":"10.1016\/j.drup.2019.100673","article-title":"Emerging roles of F-box proteins in cancer drug resistance","volume":"49","author":"Yan","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib1055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12859-018-2011-y","article-title":"Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients","volume":"19","author":"Yang","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.drup.2021.100796_bib1060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2012.06.008","article-title":"Cancer genetics and epigenetics: two sides of the same coin?","volume":"22","author":"You","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2021.100796_bib1065","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3389\/fonc.2018.00500","article-title":"The influence of metabolism on drug response in cancer","volume":"8","author":"Zaal","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2021.100796_bib1070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drup.2021.100796_bib1075","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1039\/D0SC01676D","article-title":"PI3K inhibitors: review and new strategies","volume":"11","author":"Zhang","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.drup.2021.100796_bib1080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1158\/0008-5472.CAN-20-0911","article-title":"PI3K driver mutations: a biophysical membrane-centric perspective","volume":"81","author":"Zhang","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2021.100796_bib1085","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.18632\/oncotarget.2732","article-title":"Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance","volume":"6","author":"Zhitomirsky","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2021.100796_bib1090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","article-title":"Lysosomes as mediators of drug resistance in cancer","volume":"24","author":"Zhitomirsky","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2021.100796_bib1095","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/mol.119.117978","article-title":"Wnt signaling and drug resistance in cancer","volume":"97","author":"Zhong","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drup.2021.100796_bib1100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2021.100796_bib1105","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.18632\/oncotarget.26985","article-title":"Targeted drug combination therapy design based on driver genes","volume":"10","author":"Zsakai","year":"2019","journal-title":"Oncotarget"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876462100056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876462100056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:00:10Z","timestamp":1761282010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S136876462100056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":221,"alternative-id":["S136876462100056X"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2021.100796","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer drug resistance: An update and perspective","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2021.100796","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100796"}}